Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 10 Jun 2008 |
| Genmab to Attend Three June Investor Conferences | 4 Jun 2008 |
| Grant of Warrants in Genmab A/S | 4 Jun 2008 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 4 Jun 2008 |
| Genmab Announces Appointment of David Eatwell as New Chief Financial Officer | 2 Jun 2008 |